Chongqing Zhifei Bio Products (300122) - Net Assets
Based on the latest financial reports, Chongqing Zhifei Bio Products (300122) has net assets worth CN¥15.71 Billion CNY (≈ $2.30 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥29.09 Billion ≈ $4.26 Billion USD) and total liabilities (CN¥13.38 Billion ≈ $1.96 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300122 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥15.71 Billion |
| % of Total Assets | 54.01% |
| Annual Growth Rate | 28.05% |
| 5-Year Change | -8.78% |
| 10-Year Change | 538.81% |
| Growth Volatility | 87.03 |
Chongqing Zhifei Bio Products - Net Assets Trend (2007–2025)
This chart illustrates how Chongqing Zhifei Bio Products's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Chongqing Zhifei Bio Products.
Annual Net Assets for Chongqing Zhifei Bio Products (2007–2025)
The table below shows the annual net assets of Chongqing Zhifei Bio Products from 2007 to 2025. Also explore 300122 net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥16.11 Billion ≈ $2.36 Billion |
-47.76% |
| 2024-12-31 | CN¥30.83 Billion ≈ $4.51 Billion |
-2.14% |
| 2023-12-31 | CN¥31.51 Billion ≈ $4.61 Billion |
+30.00% |
| 2022-12-31 | CN¥24.24 Billion ≈ $3.55 Billion |
+37.26% |
| 2021-12-31 | CN¥17.66 Billion ≈ $2.58 Billion |
+114.06% |
| 2020-12-31 | CN¥8.25 Billion ≈ $1.21 Billion |
+43.52% |
| 2019-12-31 | CN¥5.75 Billion ≈ $841.02 Million |
+37.47% |
| 2018-12-31 | CN¥4.18 Billion ≈ $611.80 Million |
+42.33% |
| 2017-12-31 | CN¥2.94 Billion ≈ $429.85 Million |
+16.51% |
| 2016-12-31 | CN¥2.52 Billion ≈ $368.94 Million |
+2.11% |
| 2015-12-31 | CN¥2.47 Billion ≈ $361.33 Million |
+0.47% |
| 2014-12-31 | CN¥2.46 Billion ≈ $359.64 Million |
+2.87% |
| 2013-12-31 | CN¥2.39 Billion ≈ $349.62 Million |
+0.69% |
| 2012-12-31 | CN¥2.37 Billion ≈ $347.24 Million |
+5.09% |
| 2011-12-31 | CN¥2.26 Billion ≈ $330.43 Million |
+5.43% |
| 2010-12-31 | CN¥2.14 Billion ≈ $313.40 Million |
+374.15% |
| 2009-12-31 | CN¥451.69 Million ≈ $66.10 Million |
+69.14% |
| 2008-12-31 | CN¥267.06 Million ≈ $39.08 Million |
+42.03% |
| 2007-12-31 | CN¥188.03 Million ≈ $27.52 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chongqing Zhifei Bio Products's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7359.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥12.34 Billion | 77.92% |
| Other Components | CN¥3.50 Billion | 22.08% |
| Total Equity | CN¥15.84 Billion | 100.00% |
Chongqing Zhifei Bio Products Competitors by Market Cap
The table below lists competitors of Chongqing Zhifei Bio Products ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Clear Secure Inc
NYSE:YOU
|
$4.28 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
$4.28 Billion |
|
Almonty Industries Inc. Common Shares
NASDAQ:ALM
|
$4.28 Billion |
|
Suzhou HYC Technology Co Ltd
SHG:688001
|
$4.28 Billion |
|
Ecovacs Robotics Co Ltd
SHG:603486
|
$4.28 Billion |
|
Nanjing Securities Co Ltd
SHG:601990
|
$4.27 Billion |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SHG:688266
|
$4.27 Billion |
|
ENSTAR GROUP LTD DL-01
F:48R
|
$4.27 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chongqing Zhifei Bio Products's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 30,830,739,408 to 15,839,778,819, a change of -14,990,960,589 (-48.6%).
- Net loss of 14,723,152,852 reduced equity.
- Dividend payments of 344,806,187 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-14.72 Billion | -92.95% |
| Dividends Paid | CN¥344.81 Million | -2.18% |
| Other Changes | CN¥77.00 Million | +0.49% |
| Total Change | CN¥- | -48.62% |
Book Value vs Market Value Analysis
This analysis compares Chongqing Zhifei Bio Products's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.85x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 144.77x to 1.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.08 | CN¥12.21 | x |
| 2008-12-31 | CN¥0.12 | CN¥12.21 | x |
| 2009-12-31 | CN¥0.20 | CN¥12.21 | x |
| 2010-12-31 | CN¥1.53 | CN¥12.21 | x |
| 2011-12-31 | CN¥1.43 | CN¥12.21 | x |
| 2012-12-31 | CN¥1.48 | CN¥12.21 | x |
| 2013-12-31 | CN¥1.48 | CN¥12.21 | x |
| 2014-12-31 | CN¥1.52 | CN¥12.21 | x |
| 2015-12-31 | CN¥1.55 | CN¥12.21 | x |
| 2016-12-31 | CN¥1.62 | CN¥12.21 | x |
| 2017-12-31 | CN¥1.84 | CN¥12.21 | x |
| 2018-12-31 | CN¥2.61 | CN¥12.21 | x |
| 2019-12-31 | CN¥3.59 | CN¥12.21 | x |
| 2020-12-31 | CN¥5.16 | CN¥12.21 | x |
| 2021-12-31 | CN¥11.04 | CN¥12.21 | x |
| 2022-12-31 | CN¥10.10 | CN¥12.21 | x |
| 2023-12-31 | CN¥13.13 | CN¥12.21 | x |
| 2024-12-31 | CN¥12.87 | CN¥12.21 | x |
| 2025-12-31 | CN¥6.62 | CN¥12.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chongqing Zhifei Bio Products utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -92.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -164.35%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 2.00x
- Recent ROE (-92.95%) is below the historical average (21.71%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 80.84% | 30.87% | 1.48x | 1.77x | CN¥133.21 Million |
| 2008 | 71.16% | 32.19% | 1.51x | 1.46x | CN¥163.35 Million |
| 2009 | 51.27% | 38.34% | 1.17x | 1.15x | CN¥186.42 Million |
| 2010 | 11.99% | 34.83% | 0.33x | 1.03x | CN¥42.62 Million |
| 2011 | 8.70% | 31.23% | 0.26x | 1.06x | CN¥-29.42 Million |
| 2012 | 9.06% | 28.28% | 0.30x | 1.06x | CN¥-22.25 Million |
| 2013 | 5.46% | 16.71% | 0.30x | 1.08x | CN¥-108.58 Million |
| 2014 | 6.02% | 18.48% | 0.30x | 1.10x | CN¥-97.77 Million |
| 2015 | 7.99% | 27.70% | 0.27x | 1.09x | CN¥-49.52 Million |
| 2016 | 1.29% | 7.29% | 0.16x | 1.07x | CN¥-219.61 Million |
| 2017 | 14.72% | 32.20% | 0.33x | 1.40x | CN¥138.52 Million |
| 2018 | 34.71% | 27.76% | 0.77x | 1.63x | CN¥1.03 Billion |
| 2019 | 41.17% | 22.35% | 0.97x | 1.90x | CN¥1.79 Billion |
| 2020 | 40.02% | 21.73% | 1.00x | 1.85x | CN¥2.48 Billion |
| 2021 | 57.82% | 33.30% | 1.02x | 1.70x | CN¥8.44 Billion |
| 2022 | 31.11% | 19.70% | 1.01x | 1.57x | CN¥5.12 Billion |
| 2023 | 25.61% | 15.25% | 1.05x | 1.59x | CN¥4.92 Billion |
| 2024 | 6.55% | 7.74% | 0.52x | 1.62x | CN¥-1.06 Billion |
| 2025 | -92.95% | -164.35% | 0.28x | 2.00x | CN¥-16.31 Billion |
Industry Comparison
This section compares Chongqing Zhifei Bio Products's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $4,402,542,716
- Average return on equity (ROE) among peers: 5.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chongqing Zhifei Bio Products (300122) | CN¥15.71 Billion | 80.84% | 0.85x | $4.28 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $163.30 Million | 0.76% | 1.44x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $56.30 Million | 0.00% | 2.39x | $1.39 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $282.00 Million | -7.04% | 1.16x | $403.24 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $1.01 Billion | 0.71% | 0.21x | $570.99 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.02 Billion | 4.98% | 1.21x | $1.58 Billion |
| Hualan Biological EngineeringInc (002007) | $6.88 Billion | 18.64% | 0.10x | $3.44 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $256.72 Million | 9.82% | 0.22x | $1.07 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $4.74 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.48 Billion | 2.77% | 0.29x | $426.47 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $3.22 Billion | 22.23% | 0.73x | $1.60 Billion |
About Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide… Read more